FDA assessing data manipulation concerns with gene therapy product
from Pharmacy Times
Officials with the FDA issued a statement to clarify data accuracy issues with recently-approved gene therapy Zolgensma (onasemnogene abeparvovec-xioi, AveXis), a product intended to treat spinal muscular atrophy (SMA) in children under 2 years old.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063